Company news
Alembic Limited news in 2022
Alembic Limited's news releases, calls and decks from 2022, newest first.
Alembic Pharmaceuticals receives USFDA Final Approval for Cyclophosphamide Capsules 25 mg and 50 mg
November 14, 2022
Alembic Pharmaceuticals announces its first injectable product approval from its General Sterile Facility Final Approval for Glycopyrrolate Injection USP
November 2, 2022
Alembic Pharmaceuticals receives USFDA Final Approval for Paclitaxel Injection USP, 30 mg/5 mL, 100 mg/16.7 mL, and 300 mg/50 mL Multiple-Dose Vials.
October 28, 2022
Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg.
August 30, 2022
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%
August 9, 2022
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Diclofenac Sodium Topical Gel, 3%
August 1, 2022
Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg a~d 801 mg
May 25, 2022
Alembic Pharmaceuticals announces USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg
April 8, 2022